To directly compare 19L04c and Pembrolizumab across all three mechanisms, the three immune signatures were combined in a total tumor inflammatory signature consisting of all nine cytokines and chemokines: IFNg, TNFa, IL1b, GM-CSF, CCL3, CCL4, CCL5, CXCL9, and CXCL10. The gene discussed is CCL5; the disease is neoplasm.